Celldex Therapeutics (CLDX) Retained Earnings (2010 - 2026)

Celldex Therapeutics' Retained Earnings history runs 17 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• In Q1 2026, Retained Earnings rose 100.16% year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $2.5 million (up 100.16% YoY), while the FY2025 annual figure was -$1.8 billion, down 16.64% from the prior year.
• Retained Earnings was $2.5 million for Q1 2026 at Celldex Therapeutics, up from -$1.8 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $3.3 million in Q4 2023 to a low of -$1.8 billion in Q4 2025.
• Historically, Retained Earnings has averaged -$872.9 million across 5 years, with a median of -$1.2 billion in 2022.
• Biggest YoY gain for Retained Earnings was 100.26% in 2023; the steepest drop was 315438.37% in 2023.
• A 5-year view of Retained Earnings shows it stood at -$1.3 billion in 2022, then soared by 100.26% to $3.3 million in 2023, then plunged by 47114.03% to -$1.6 billion in 2024, then fell by 16.64% to -$1.8 billion in 2025, then jumped by 100.14% to $2.5 million in 2026.
• The last three Retained Earnings figures came in at $2.5 million (Q1 2026), -$1.8 billion (Q4 2025), and -$1.7 billion (Q3 2025), per Business Quant data.